New supply agreement enhances QuidelOrtho's immunoassay offerings globally.
- QuidelOrtho strengthens its diagnostic test offerings.
- The agreement is aimed at expanding global health access.
- Advancements in immunoassay technology are prioritized.
QuidelOrtho has announced a strategic supply agreement intended to expand its QuidelOrtho immunoassay portfolio. This new agreement aims to enhance the company's offerings in diagnostic tests worldwide. By focusing on immunoassay technology, QuidelOrtho is likely to improve its role in global health.
The agreement will facilitate the distribution of various immunoassays, which are critical for diagnosing a wide range of medical conditions. Through this partnership, QuidelOrtho aims to make diagnostic testing more accessible to healthcare providers and patients. This initiative underscores the company's commitment to advancing healthcare solutions globally.
As part of this strategic push, QuidelOrtho is poised to leverage innovative immunoassay technology to enhance the capabilities of its diagnostic products. The initiative aims to respond to the increasing demand for reliable and efficient testing options in the healthcare sector.
